SweetValueLab
Write for us

Abbott Laboratories — Wall Street Analyst Estimates & Price Targets

ABT
NYSEHealthcareMedical - DevicesCIK 0000001800abbott.comAbout ABT
Last close · Oct 16, 2026104.88+0.20 (+0.19%)
Market cap$181.5B

6 firms' latest targets, last 90 days: median $122.50 ($120.00–$130.00), 17% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$80.0$100$120$140$160NovJan 2026MarMayJulSep2025-10-17 · Barclays: $1622025-11-21 · Tigress Financial: $1452025-12-22 · BTIG: $1452026-01-05 · Evercore ISI: $1442026-01-05 · Barclays: $1692026-01-09 · Bernstein: $1542026-01-09 · Goldman Sachs: $1522026-01-23 · Evercore ISI: $1382026-01-23 · UBS: $1322026-01-23 · Mizuho Securities: $1252026-01-23 · Piper Sandler: $1352026-01-23 · Bernstein: $1252026-01-23 · Wells Fargo: $1222026-01-29 · Loop Capital Markets: $1202026-02-02 · Barclays: $1422026-03-13 · UBS: $1582026-03-13 · New Street: $1452026-04-17 · UBS: $1152026-04-17 · Piper Sandler: $1152026-04-17 · Stifel: $1202026-04-20 · Barclays: $1432026-04-22 · Daiwa: $92.02026-06-30 · Baird: $1212026-07-06 · Evercore ISI: $1122026-07-16 · BTIG: $1342026-07-17 · Piper Sandler: $1182026-07-20 · Benchmark: $1202026-07-28 · UBS: $1252026-08-13 · Wolfe Research: $1302026-10-02 · Rothschild & Co Redburn: $1272026-10-06 · Barclays: $1202026-10-16 · New Street: $120
$80.0$100$120$140$160NovFebMayAug

Each firm's latest target

last 90 days · 6 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-16New Street$120.00$145.00▼ 17%+15%+14%
2026-10-06Barclays$120.00$143.00▼ 16%+22%+14%
2026-10-02Rothschild & Co Redburn$127.00——+31%+21%
2026-08-13Wolfe Research$130.00——+17%+24%
2026-07-28UBS$125.00$115.00▲ 9%+15%+19%
2026-07-20Benchmark$120.00——+19%+14%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$40.1B-8%$3.26-17%est. $40.1B+0%est. $4.4415
2024reported$42.0B+5%$7.64+134%est. $42.0B+0%est. $4.6716
2025reported$44.3B+6%$3.72-51%est. $44.7B-1%est. $5.1518
2026$50.3B+13%$5.52+7%$50.2B–$50.4B$5.48–$5.5721
2027$54.7B+9%$6.07+10%$53.6B–$55.3B$6.01–$6.1921
2028$58.5B+7%$6.73+11%$53.8B–$59.8B$4.55–$7.6620
2029$63.2B+8%$7.47+11%$60.2B–$64.0B$7.01–$7.5910
2030$67.8B+7%$8.29+11%$64.7B–$68.7B$7.79–$8.4310
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.